Science and Evidence

Direct answer

Laboratory and animal research support concern about 7-OH's opioid activity and dependence potential. They do not establish a safe human dose, a universal potency multiplier, or the number of deaths caused by isolated 7-OH. Kruegel et al. 2016 receptor study Matsumoto et al. 2005 tolerance and withdrawal study

What receptor studies show

A receptor is a cellular target; binding measures interaction with it, while functional tests measure activation. Kruegel and colleagues studied mitragynine and 7-OH at opioid receptors and found partial agonist activity at human mu-opioid receptors in their assay. They also investigated signaling pathways. Kruegel et al. 2016 receptor study

"Partial agonist" and a particular signaling profile are laboratory descriptions, not guarantees against overdose. A receptor experiment cannot reproduce all the effects of a retail mixture in a person.

What animal studies show

Matsumoto and colleagues studied pain responses, repeated exposure, and withdrawal in mice. Tolerance developed to 7-OH's pain-response effect, and withdrawal was observed in a naloxone-precipitated experimental model. These results support physical-dependence potential; they are not a human withdrawal timetable. Matsumoto et al. 2005 tolerance and withdrawal study

The distinction matters: evidence can identify a hazard without specifying how often it occurs among consumers. Conversely, an animal result cannot establish that a particular person has a substance-use disorder.

How to read potency headlines

A comparison such as "13 times more potent than morphine" requires the assay, endpoint, and species. FDA repeats a reported guinea-pig intestinal-tissue comparison. The original paper's printed response values do not reproduce that ratio, so it remains a reported figure, not an independently verified multiplier. Original paper, page 2148 FDA assessment

Do not use a potency headline to calculate a dose or infer that every marketed product is thirteen times as dangerous. A milligram amount is not meaningful without knowing the compound and formulation.

What human reports can and cannot tell us

FDA's assessment reviews poison-center, toxicology, and other surveillance signals. It also explains that detection can be difficult to attribute to a particular product because related alkaloids, metabolites, and other substances may be present. A detected compound is not by itself proof of a single cause of death. FDA 7-OH scientific assessment

Reports can alert researchers to a problem. They do not automatically provide a representative sample, an incidence rate, or a controlled comparison with botanical leaf.

What remains uncertain?

Important questions include the effects of repeated isolated 7-OH exposure in humans, product-specific risks, interactions, and the best treatment approaches. Do not turn those gaps into either a claim of safety or a claim that every severe outcome has been conclusively attributed to 7-OH.

FDA's clinician letter nonetheless warns about serious breathing and withdrawal risks. That warning supports taking symptoms seriously while remaining precise about evidence. FDA letter to health care professionals

Science and regulation are different records

The FDA scientific assessment is dated 2025; FDA's public-health page now includes an October 2026 regulatory update. A regulatory update is not a new clinical trial. FDA October 2026 7-OH update

For the dated legal record, read the Regulatory Tracker. For practical support, read Get Help.